Exploring Genetically Modified Animals for Development of New Atherosclerosis Treatments in NHLBI
- Corresponding Author:
- Boris L Vaisman, Ph.D
National Institutes of Health, Building 10, Room 8N226
10 Center Drive MSC 1666, Bethesda, MD 20892-1666, USA
E-mail: [email protected]
Received date: March 14, 2014; Accepted date: June 14, 2014; Published date: July 14, 2014
Citation: Vaisman BL, Freeman L, and Remaley AT (2014) Exploring Genetically Modified Animals for Development of New Atherosclerosis Treatments in NHLBI. J Mol Genet Med 8:109. doi: 10.4172/1747-0862.1000109
Copyright: © 2014 Vaisman BL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Development of New Animal Models of Atherosclerosis Atherosclerosis and complications associated with this pathology, such as coronary artery disease, remains a leading cause of morbidity and mortality in the world . Dyslipidemia is one of the main risk factors leading to development of the atherosclerosis [2,3]. Peripheral (non-hepatic) cells, including arterial and aortic cells, obtain cholesterol from either de novo synthesis or from uptake of plasma lipoproteins. To prevent atherosclerosis, excess cholesterol must be removed from cells. This process takes place through the reverse cholesterol transport pathway [4,5], a process whereby cells efflux excess cholesterol to HDL, which subsequently delivers cholesterol to the liver for excretion into the bile.